Stopping Mounjaro (tirzepatide) is not known to cause a withdrawal syndrome. However, your appetite may gradually return as the medicine leaves your body, and some people regain some of the weight they lost during treatment. This pattern has been seen in clinical trials, so understanding what the evidence shows can help you plan for what comes next.
One of the most informative studies is the SURMOUNT 4 trial, which looked at what happened when people stopped taking tirzepatide. On average, people who stopped treatment regained 14% of their body weight over the following year, while those who continued treatment lost additional weight. Individual results varied, so this figure should not be treated as a prediction of what will happen to you.
This guide explains what the research shows, what you may notice after your final dose, and what you can discuss with your prescriber if you are concerned about weight regain.
If you are considering stopping Mounjaro, discussing your plans with your prescriber beforehand can help you understand your options and plan appropriate follow up.
Key things to know
- In the SURMOUNT 4 trial, people who stopped tirzepatide after 36 weeks regained an average of 14% of their body weight over the following year.
- Among participants who had lost at least 10% of their body weight before stopping, 82% regained more than a quarter of the weight they had lost within a year.
- Tirzepatide is not known to cause a withdrawal syndrome. Changes after stopping are thought to be related mainly to the medicine's effects wearing off and appetite returning, rather than physical dependence.
- People who continued tirzepatide in the SURMOUNT 4 trial lost additional weight, showing that stopping treatment and continuing treatment can lead to different outcomes.
- Weight regain does not happen to exactly the same degree in everyone. Your response can be influenced by factors such as appetite, eating patterns, physical activity and your wider health.
What the Evidence Actually Shows About Stopping Tirzepatide
The SURMOUNT 4 trial, published in JAMA in 2023, followed adults with obesity or overweight who had completed 36 weeks of treatment with tirzepatide. Participants were then randomly assigned either to continue tirzepatide or switch to a placebo for another year.
Those who continued treatment lost a further 5.5% of their body weight on average. Those who switched to placebo regained an average of 14% of their body weight during the same period. Around 9 in 10 people who continued treatment maintained at least 80% of their previous weight loss, compared with around 1 in 6 people who switched to placebo.
A later analysis published in JAMA Internal Medicine looked specifically at people who had lost at least 10% of their body weight before stopping treatment. In this group, 82% regained more than a quarter of the weight they had lost within a year. The analysis also found that some of the improvements in blood pressure, cholesterol and blood sugar seen during treatment moved back towards baseline as weight was regained.
These results show why weight regain after stopping tirzepatide is a real possibility, but they do not mean that everyone will regain the same amount of weight.
Why Weight Regain Happens After Stopping
Tirzepatide, the active ingredient in Mounjaro, acts on GLP 1 and GIP pathways involved in appetite regulation. It can reduce appetite and increase feelings of fullness. It also slows gastric emptying, particularly during the early stages of treatment.
Once treatment is stopped, these effects gradually wear off as the medicine leaves the body. Appetite may increase again, which can make it harder to maintain the reduced food intake that supported weight loss.
This is a physiological response and does not mean that you have failed or done anything wrong. Weight regulation is influenced by several biological and environmental factors, and obesity is increasingly recognised as a chronic condition that may require long term management for some people.
If you are concerned about regaining weight, speak with your prescriber before stopping treatment. They can help you understand what to expect and discuss what ongoing support may be appropriate for you.
A Realistic Week by Week Timeline After Your Last Dose
Tirzepatide has an elimination half life of around 5 days. It therefore takes several weeks for the medicine to be largely cleared from the body after the final dose. This helps explain why changes after stopping are usually gradual rather than immediate.
During the first one to two weeks after your final dose, you may notice little difference in your appetite because a meaningful amount of tirzepatide is still present in your body. Some people may notice changes sooner, while others may not notice an obvious difference.
During roughly weeks two to four, the effects of treatment may continue to wear off as tirzepatide levels fall. You may notice your appetite or interest in food increasing, although the timing varies between individuals.
By around four to five weeks, most of the medicine will have been cleared from your body. This does not mean that your weight will suddenly change at this point. Rather, the direct effects of tirzepatide on appetite and other processes will have reduced substantially.
Over the following two to three months, your weight may be influenced by how well your eating patterns, physical activity and other weight management strategies are maintained without the medicine. Some people may need additional support during this period, so staying in contact with your prescriber can be helpful if you notice significant changes in appetite or weight.
Managing the Transition: What Helps
The SURMOUNT 4 data does not mean that weight regain is unavoidable. It shows what happened on average in the study, with considerable variation between individuals. Structured eating patterns, adequate protein intake and regular physical activity can support weight management after treatment. Behavioural strategies may also be useful as appetite and food cravings change. A balanced diet that includes lean protein, fibre rich and nutrient dense foods, and wholegrain carbohydrates can help you maintain a varied diet while managing your overall food intake.
Planning ahead can also help. Strengthening healthy habits while you are still on treatment, rather than waiting until after stopping, gives you time to build a routine before appetite changes become more noticeable. Some people may find it useful to keep a simple food and weight log during the transition. Weighing yourself once or twice a week can help you notice changes and discuss them with your healthcare professional if needed, rather than focusing on daily fluctuations.
A structured exercise routine that includes strength based activity can help support muscle strength and overall health. General UK guidance recommends that adults aim for at least 150 minutes of moderate intensity physical activity each week, alongside muscle strengthening activities on at least 2 days a week. Getting enough sleep may also support healthy eating patterns and overall weight management.
Is There a Way to Reduce Regain?
Some prescribers may discuss ongoing treatment options based on your individual response and circumstances. In the SURMOUNT 4 trial, people who continued tirzepatide lost more weight on average, while those who stopped treatment regained weight on average. This does not mean that continuing treatment will prevent weight regain for every person.
There is currently no established or licensed tapering protocol for tirzepatide. Some clinicians may discuss different approaches to stopping treatment, but this is an individual clinical decision based on factors such as your response to treatment, side effects and reason for stopping.
There is no officially required tapering schedule for stopping tirzepatide, unlike with some other types of medicine. If you are considering stopping Mounjaro, discuss your options with your prescriber beforehand rather than changing your treatment yourself. They can explain the potential benefits and limitations of different approaches and help you plan for changes in appetite or weight.
When to Speak to Your Prescriber Before Stopping
If you are considering stopping Mounjaro for any reason, whether you have reached a personal goal, are concerned about side effects, or are considering the cost of treatment, it is worth speaking with your prescriber first. This is particularly important if tirzepatide has been prescribed as part of diabetes management.
Your prescriber can talk through what to expect based on your treatment history and discuss whether continuing treatment, changing your treatment plan or stopping may be appropriate. They can also help you plan your eating habits, physical activity and follow up after stopping treatment.
If you experience concerning symptoms after stopping, significant mood changes, rapid unexplained changes in weight or any new health concerns, contact your prescriber rather than assuming these are simply part of the transition.
Continuing or Restarting Treatment at EverydayMeds
If you and your prescriber decide that continuing or restarting treatment is appropriate, EverydayMeds offers Mounjaro following an online clinical consultation with UK registered prescribers as part of a broader weight management pathway. The standard price for a single pen (4 weeks) at the 2.5mg starting dose is £174.99. Current promotional pricing, if available, is shown at checkout.
Medical Disclaimer
This page provides general information about what may happen after stopping tirzepatide, based on published clinical trial data. It is not a substitute for personalised medical advice. Decisions about stopping, continuing or changing your dose should be made with your prescriber, based on your individual circumstances and treatment needs.
